Magali Svrcek

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2018 · 2K citations · Full text

Immunology, Pathology, Immunotherapeutics +18

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features

Francesco Puleo, Rémy Nicolle, Yuna Blum et al. · Gastroenterology · 2018 · 553 citations

Tumor Biology, Pancreatic Cancer, Tumor Heterogeneity +8

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

Thierry André, David Tougeron, Guillaume Piessen et al. · Journal of Clinical Oncology · 2022 · 345 citations · Full text

Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma

Raphaël Maréchal, Jean‐Baptiste Bachet, John R. Mackey et al. · Gastroenterology · 2012 · 236 citations · Full text

Pancreatic Cancer, Patients Treated, Medicine +8

ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology

Fernando Magro, Glen Doherty, Laurent Peyrin‐Biroulet et al. · Journal of Crohn s and Colitis · 2020 · 187 citations · Full text